Biomed Realty Trust (NYSE: BMR) is one of 75 publicly-traded companies in the “Commercial REITs” industry, but how does it contrast to its competitors? We will compare Biomed Realty Trust to related companies based on the strength of its earnings, dividends, institutional ownership, analyst recommendations, valuation, profitability and risk.
This is a summary of recent recommendations for Biomed Realty Trust and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Biomed Realty Trust||0||0||0||0||N/A|
|Biomed Realty Trust Competitors||595||2513||2036||24||2.29|
As a group, “Commercial REITs” companies have a potential upside of 4.79%. Given Biomed Realty Trust’s competitors higher possible upside, analysts clearly believe Biomed Realty Trust has less favorable growth aspects than its competitors.
Biomed Realty Trust pays an annual dividend of $1.04 per share and has a dividend yield of 4.4%. Biomed Realty Trust pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Commercial REITs” companies pay a dividend yield of 4.0% and pay out 90.1% of their earnings in the form of a dividend. Biomed Realty Trust has raised its dividend for 7 consecutive years.
Valuation & Earnings
This table compares Biomed Realty Trust and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Biomed Realty Trust||N/A||N/A||22.89|
|Biomed Realty Trust Competitors||$537.26 million||$100.34 million||392.57|
Biomed Realty Trust’s competitors have higher revenue and earnings than Biomed Realty Trust. Biomed Realty Trust is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Biomed Realty Trust and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Biomed Realty Trust||18.98%||3.73%||2.07%|
|Biomed Realty Trust Competitors||52.83%||6.47%||3.79%|
Institutional & Insider Ownership
73.1% of shares of all “Commercial REITs” companies are held by institutional investors. 7.3% of shares of all “Commercial REITs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Biomed Realty Trust competitors beat Biomed Realty Trust on 8 of the 9 factors compared.
Biomed Realty Trust Company Profile
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT). The Company is the parent company and general partner of BioMed Realty, L.P. The Company owns, acquires, develops, redevelops, leases and manages laboratory and office space for the life science industry. The Company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company’s properties are located in markets, which has centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York, New Jersey, Pennsylvania, North Carolina, Seattle, Cambridge (the United Kingdom) and research parks located near or adjacent to universities and their related medical systems. The Company owns interests in properties comprising approximately 17.5 million rentable square feet.
Receive News & Ratings for Biomed Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomed Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.